Fig. 5

Effects of GPR39 and PGC-1α CRISPR, and SIRT1 inhibitor EX527 with TC-G 1008 on infarct volume, neurological function and body weight at 48-h post-HIE. A, B Animal groups treated with GPR39 CRISPR or PGC-1α CRISPR, or EX527 have significant greater proportion of infarction when compared with respective controls treated with TC-G 1008. C, D Animal groups treated with GPR39 CRISPR or PGC-1α CRISPR, or EX527 significantly abolished the neurological benefit of TC-G 1008 when compared with respective controls. E TC-G 1008 treatment or TC-G 1008 with DMSO significantly attenuated HIE-induced body weight loss, which were reversed by GPR39 CRISPR or PGC-1α CRISPR, or EX527. *p < 0.05 vs. sham; ^#p < 0.05 vs. HIE + vehicle; ^@p < 0.05 vs. HIE + TC-G1008 + control CRISPR; ^$p < 0.05 vs. HIE + TC-G1008 + DMSO. n = 6 for each group